Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
April 3rd, 2018
8.9K views
Here we describe a protocol for employing high-throughput RNAi screening to uncover host targets that can be manipulated to enhance oncolytic virus therapy, specifically rhabodvirus and vaccinia virus therapy, but it can be readily adapted to other oncolytic virus platforms or for discovering host genes that modulate virus replication generally.
Overview
This protocol outlines a method for high-throughput RNAi screening to identify host targets that can enhance oncolytic virus therapy, particularly for rhabdovirus and vaccinia virus. It is adaptable for other oncolytic virus platforms and for discovering host genes that influence virus replication.
Key Study Components
Area of Science
- Oncolytic virus therapy
- RNA interference (RNAi)
- Host-pathogen interactions
Background
- Oncolytic viruses are designed to selectively infect and kill cancer cells.
- Understanding host factors can improve the efficacy of oncolytic virus therapies.
- High-throughput screening allows for comprehensive identification of relevant host targets.
- This protocol can be adapted for various viral platforms.
Purpose of Study
- To identify host targets that can be manipulated to enhance oncolytic virus therapy.
- To explore host factors and cellular pathways that modulate virus replication.
- To provide a comprehensive and unbiased method for target identification.
Methods Used
- Development of a high-throughput screening assay.
- Preparation of microtiter plates for screening.
- Use of RNAi to knock down host genes.
- Analysis of viral replication in response to host target manipulation.
Main Results
- Identification of specific host factors that enhance oncolytic virus therapy.
- Insights into cellular pathways that influence virus replication.
- Demonstration of the effectiveness of high-throughput RNAi screening.
- Potential for broader applications in understanding virus-host interactions.
Conclusions
- The protocol provides a valuable tool for enhancing oncolytic virus therapies.
- Identifying host targets can lead to improved therapeutic strategies.
- This method can be adapted for various research applications in virology.
Frequently Asked Questions
What is the main goal of this protocol?
The main goal is to identify host targets that can enhance oncolytic virus therapy.
How does this protocol contribute to oncolytic virus research?
It allows for the unbiased identification of host factors that modulate virus replication.
Can this method be used for other types of viruses?
Yes, it can be adapted for various oncolytic virus platforms.
What are the advantages of high-throughput RNAi screening?
It enables comprehensive and unbiased identification of relevant host targets.
What is the significance of understanding host factors?
Understanding host factors can lead to improved efficacy of oncolytic virus therapies.
What is the initial step in the protocol?
The initial step involves preparing microtiter plates and reagents for screening.
Executive Industry Relevance
Genome-wide RNAi screening enables unbiased identification of host factors that modulate oncolytic virus replication, providing a systematic approach to de-risk therapeutic target selection in early discovery. By mapping host-pathogen interactions that influence viral infectivity, burst size, and cytotoxicity, the method supports predictive confidence in target validation and portfolio prioritization. This capability enhances mechanistic understanding and informs go/no-go decisions in oncolytic virus development pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by identifying host genes that modulate virus replication in cancer cells.
- Operational Value: Provides a comprehensive, unbiased survey of host factors across the genome to clarify pathway involvement.
- Scientific Value: Supports biological de-risking of targets by linking host factor modulation to measurable changes in viral oncolytic activity.
Screening & Assay Development
- Scientific Value: Establishes a standardized, reproducible assay system for quantifying virus replication phenotypes such as infectivity and cytopathic effect.
- Operational Value: Generates quantitative, high-content data suitable for hit selection and downstream validation workflows.
- Scientific Value: Facilitates assay scalability and cross-platform applicability to other oncolytic viruses beyond Maraba and vaccinia.
Translational & Preclinical Research
- Scientific Value: Identifies host targets with disease relevance in tumor cell lines, supporting translational biomarker alignment.
- Operational Value: Enables secondary and tertiary validation using orthogonal siRNA sequences to confirm target specificity.
- Scientific Value: Supports risk-adjusted advancement decisions by confirming hits across multiple cancer cell lines using robust statistical methods (MAD).
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target identification through preclinical validation, enabling hypothesis-driven interrogation of host pathways that influence oncolytic virus efficacy.
- Discovery Biology: Supports hypothesis testing and pathway clarification by linking host gene knockdown to changes in viral replication dynamics.
- Screening: Delivers assay readiness and quantitative outputs (e.g., survival plots, infection metrics) that enable reliable compound or genetic perturbation evaluation.
- Analytics: Generates statistical outputs (e.g., MAD-based hit calling) that allow cross-condition comparison and prioritization of candidates.
- Translational Research: Connects discovery findings to preclinical continuity by validating hits in multiple tumor models and linking them to known pathways (UPR, ERAD).
- Enterprise Reuse: Establishes a reusable screening capability applicable to various oncolytic virus platforms and general virus-host interaction studies.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity in host-pathogen interactions.
- Operational Value: Standardization, reproducibility, and scalability of high-throughput RNAi screening workflows.
- Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk through early target de-risking.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on validated host targets across multiple cancer models.
Implementation Considerations
- Requires expertise in cell culture, transfection, and high-throughput liquid handling.
- Dependent on access to RNAi libraries, transfection reagents, and imaging platforms for viral replication readouts.
- Necessitates cross-team standardization of assay conditions, reagent handling, and data analysis protocols.
- Involves adaptation considerations across different tumor cell lines and virus strains to ensure assay relevance.
- Practical limitations include reagent toxicity, off-target effects, and the need for orthogonal validation to confirm hit specificity.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in RNAi screens?
Null hypothesis testing ensures that observed changes in viral replication are statistically significant and not due to random variation, which is critical for confidently identifying true host factors that modulate oncolytic virus therapy.
How does independent variable isolation fit the discovery pipeline in host factor screening?
Isolating the independent variable (e.g., specific siRNA knockdown) allows researchers to attribute changes in viral replication directly to the targeted host gene, enabling mechanistic de-risking and reliable target validation in early discovery.
What quantitative dependent variable measurements enable hit selection in RNAi-based virus screens?
Quantitative measurements such as cell survival, infection rates, and viral burst size provide objective, numerical readouts that enable ranking and prioritization of host factors based on their impact on virus replication.
Why do replication requirements matter for cross-functional collaboration in high-throughput screening?
Replication requirements ensure that findings are consistent across experiments and cell lines, which builds confidence in target validity and supports alignment between discovery, assay development, and preclinical teams.
What statistical analysis capabilities are required before implementing a genome-wide RNAi screen for virus therapy?
Robust statistical methods such as median absolute deviation (MAD) are required to normalize data, account for plate effects, and identify significant hits while minimizing false positives in large-scale screening campaigns.
